MAT (Medication Assisted Treatment) Formulary Changes effective 3/22/2022



On December 22, 2021, Governor Hochul changed the Social Services and the Public Health Law, a law relating to medication for the treatment of substance use disorders. Effective March 22, 2022, prior authorization (PA) will not be required for medications used for the treatment of substance use disorder prescribed according to generally accepted national professional guidelines for the treatment of a substance use disorder.

A Single Statewide Medication Assisted Treatment (MAT) Formulary was implemented for Medicaid Managed Care Plans and Medicaid-Fee-for-Service in New York State on October 1, 2021. For more information, please visit the online <u>Single Statewide</u> <u>MAT Formulary</u>.

Please see summary of changes below.

For SelectHealth Formulary: <u>selecthealthny.org/drugcoverage</u> For Prior Authorizations (Providers only): 1-888-678-7741 For Prior Authorization fax form: click <u>here</u> and fax to 1-858-790-7100

Opioid Antagonists

Formulary/Preferred	Coverage Parameters
Narcan (nasal spray)	Narcan QL 2 units/fills
Naloxone (nasal spray)	Naloxone QL 2 units/fills
Kloxxado	
Naltrexone	None
naloxone (syringe, vial)	None

Opioid Dependence Agents – Injectable

Formulary/Preferred	Coverage Parameters
Sublocade	None
Vivitrol	None

Opioid Dependence Agents - Oral/Transmucosal

Formulary/Preferred	Coverage Parameters
buprenorphine sublingual (SL) tablets	Clinical Criteria (CC): Prior Authorization required for opioids when member has a history of
buprenorphine/ naloxone film	buprenorphine
Suboxone film	(mono or combo) product in last 30 days
buprenorphine/naloxone tablets	Prior Authorization required for buprenorphine SL tabs when member has a history of 6
Zubsolv	buprenorphine SL tablets in the prior 90 days.
	Prior Authorization required for buprenorphine SL tabs when member has a history of at least 7 days of buprenorphine/naloxone therapy in the prior 30 days
	Quantity Limit (QL): buprenorphine SL tabs: Three 8 mg or twelve 2 mg tablets/day
	buprenorphine/naloxone tablet and film (Bunavail, Suboxone, Zubsolv up to 5.7mg/1.4mg strength): Three tablets or films per day
	buprenorphine/naloxone tablet (Zubsolv 8.6mg/2.1mg and Suboxone 12mg/3mg strengths): Two tablets per day
	buprenorphine/naloxone tablet (Zubsolv 11.4mg/2.9mg strength): One tablet per day

If you have any questions, please call the SelectHealth Care Team at 1-866-469-7774 (TTY: 711), 8 am – 6 pm, Monday – Friday.

This notice is also available in other formats for members with special needs or members who speak languages other than English. Please call the phone number listed above for help.